Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05616793 |
Recruitment Status :
Recruiting
First Posted : November 15, 2022
Last Update Posted : June 18, 2023
|
Sponsor:
Opus Genetics, Inc
Information provided by (Responsible Party):
Opus Genetics, Inc
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Recruiting |
---|---|
Estimated Primary Completion Date : | August 30, 2024 |
Estimated Study Completion Date : | September 30, 2027 |